Answers are grounded in this paper and cite their sources.
The COVID-19 pandemic has highlighted the need for effective treatments and underscored the urgent need for effective therapeutic agents.This comprehensive review explores the potential of traditional medicinal and aromatic plants as therapeutic agents against COVID-19 and delves into the rich pharmacological potential of these plants, which have been used for centuries in traditional medicine systems worldwide.The review discusses various bioactive metabolites and plant products derived from these plants, highlighting their potential antiviral, anti-inflammatory, and immune-boosting properties.It also examines herba l formulations such as AYUSH kwath, AYUSH-64, agasthya hareetaki, and anuthalia recommended by AYUSH and other traditional medicine systems, assessing their potential efficacy against COVID-19 based on available scientific evidence including routinely used medicinal plants.Plant-based preparations include antiviral, antibacterial, and anticancer therapies and their possible therapeutics against COVID-19.Limited, unregulated clinical trials involving conventional mono and poly-herbal therapies are being conducted worldwide.Some clinical trials have reached completion, but doubts about safety and efficacy persist even with the recent invention of vaccines.Meta-analyses have shown favourable effects of herbal medicine when added to standard treatment for COVID-19.These effects include improvements in the total effective rate, time to remission from fever, coughing, fatigue, sputum production, and more.Traditional Chinese medicine (TCM) combined with conventional western medicine has shown positive outcomes in treating COVID-19.Lung CT parameters and clinical cure rates were better with TCM combined therapy for mild to moderate cases.Chinese herbal medicines combined with conventional therapy improved lung CT parameters and clinical cure rates compared to conventional therapy alone.NRICM102, composed of 10 herbs, has shown effectiveness in improving pulmonary fibrosis in animal experiments and preliminary clinical trials.However, further research is needed to fully understand their potential and address the challenges involved.
No takes yet. Share an insight, caveat, or question.
Banu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: